Curanex Pharmaceuticals Inc. (CURX) - 10-K Summary
Business Context and Reporting Period
Company: Curanex Pharmaceuticals Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Curanex is a developmental-stage pharmaceutical company focused on discovering, developing, and commercializing botanical drugs for inflammatory diseases. The company's lead candidate, Phyto-N, is a proprietary botanical extract with a history of use in Chinese traditional medicine. The company targets six core indications: ulcerative colitis (lead), atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease (NAFLD), and gout.
Recent Milestones: The company completed its Initial Public Offering (IPO) on August 27, 2025, listing on the Nasdaq Capital Market under the symbol "CURX." In February 2026, the company completed a GMP pilot-scale batch of Phyto-N and a dose-range finding toxicology study, positioning it for an Investigational New Drug (IND) application submission in Q4 2026.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(4,225,106) | $(361,506) |
| Operating Expenses | $4,239,076 | $365,062 |
| Research & Development (R&D) | $2,985,873 | $74,676 |
| General & Administrative (G&A) | $1,253,203 | $290,386 |
| Cash and Cash Equivalents (Year End) | $4,973,134 | $148,891 |
| Total Assets | $11,580,124 | $517,935 |
| Total Liabilities | $361,040 | $14,575 |
Liquidity: As of December 31, 2025, the company held approximately $5.0 million in cash, primarily derived from net IPO proceeds of ~$15.3 million. Management believes this is sufficient to fund operations for at least the next 12 months.
Material Changes vs. Prior Period
- Revenue: No revenue was generated in either period as the company remains in the preclinical development stage.
- Net Loss: Net loss increased significantly by approximately $3.86 million (958% increase) from 2024 to 2025. This was driven by a surge in R&D expenses related to IND-enabling studies and increased G&A costs associated with becoming a public company (personnel compensation, professional fees).
- Capital Structure: The company raised approximately $15.3 million in net proceeds from its IPO and the full exercise of the over-allotment option in late 2025. This resulted in a substantial increase in cash balances and shareholders' equity.
- Prepaid Expenses: Prepaid R&D expenses increased to $6.2 million, reflecting advance payments to Contract Research Organizations (CROs) and Contract Development and Manufacturing Organizations (CDMOs).
Guidance, Outlook, and Risks
Outlook and Guidance:
- IND Submission: Targeted for Q4 2026 for the treatment of ulcerative colitis.
- Clinical Trials: Phase I trials are planned to initiate in Australia in Q4 2026, contingent on FDA clearance.
- Future Funding: The company estimates it will require over $150 million to execute its full business plan through FDA approval and product launch. Future funding will likely come from equity/debt financings or strategic partnerships.
Management Commentary: Management emphasizes the "pipeline in a product" strategy for Phyto-N, aiming to address multiple inflammatory indications. The company has successfully completed GMP manufacturing and dose-range finding toxicology studies, keeping the program on schedule.
Risks and Contingencies:
- Nasdaq Listing Deficiency: On November 5, 2025, the company received notice that its stock price fell below the $1.00 minimum bid price requirement. It has a compliance period until May 4, 2026, to regain compliance or risk delisting.
- Internal Controls: Management identified material weaknesses in internal controls over financial reporting as of December 31, 2025, including a lack of US GAAP experienced personnel and inadequate bookkeeping systems. Disclosure controls were deemed ineffective.
- Regulatory Uncertainty: As a botanical drug developer, the company faces unique regulatory challenges. Only four botanical drugs have received FDA approval to date. There is no assurance Phyto-N will receive approval.
- Intellectual Property: The company relies on a PCT application filed in March 2025 to protect its IP; there is no assurance of patent issuance.
Key Facts for Investor Verification
- Going Concern Status: Verify the company's ability to maintain liquidity beyond the 12-month horizon given the estimated $150 million capital requirement for full development.
- Nasdaq Compliance: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement by May 4, 2026, to avoid delisting.
- Internal Control Remediation: Track progress on remediation of material weaknesses in financial reporting and internal controls.
- IND Timeline: Confirm the submission of the IND application for ulcerative colitis in Q4 2026 as planned.
- Prepaid R&D Utilization: Monitor the burn rate of the $6.2 million in prepaid R&D expenses to ensure they align with the projected clinical milestones.